RxDoctor Payments Data

Bhavna Gowda, MD

Family Medicine · Hartselle, ALNPI 1750557518

Payments from drug & device makers

$1,560in general payments, 2019–2025

Across 79 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$345
  • Pfizer$280
  • AbbVie$191
  • GSK$167
  • Novo Nordisk$102
  • Merck$85
  • plus $391 from 12 others

What the payments were for

  • Food & beverage$1,560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,560 in reported general payments places this provider in the 60th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$160,638
Medicare patients
272
Services billed
3,173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide175$192,465
JanuviaSitagliptin Phosphate117$114,917
MounjaroTirzepatide85$101,799
JardianceEmpagliflozin81$94,409
EliquisApixaban71$71,889
TrulicityDulaglutide31$31,825
XareltoRivaroxaban18$18,255
LinzessLinaclotide16$16,710
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$13,519
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$12,361
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$9,093
Incruse ElliptaUmeclidinium Bromide25$8,630
EntrestoSacubitril/Valsartan13$7,503
Breo ElliptaFluticasone/Vilanterol13$7,488
Albuterol Sulfate HfaAlbuterol Sulfate194$7,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$102$192,465175 claims
Lilly USA, LLCMounjaro, Trulicity$345$133,624116 claims
MerckJanuvia$85$114,917117 claims
PfizerEliquis, Premarin$280$75,10782 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$167$28,48054 claims
AbbVieLinzess$191$16,71016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Hartselle

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →